Open AccessRelationship between driver gene mutations, their relative protein expressions and survival in non‐small cell lung carcinoma in Macao
Author(s) -
Chan Kin Iong,
Vong Hong Ting,
Sin Lai Fong,
Yip Yuk Ching,
Zhong Xue Yun,
Wen Jian Ming
Publication year - 2018
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12670
Subject(s) - kras , medicine , fluorescence in situ hybridization , lung cancer , immunohistochemistry , mutation , cancer research , concordance , gene mutation , carcinoma , oncology , gene duplication , gene , pathology , cancer , biology , genetics , colorectal cancer , chromosome
Objectives We report the status of most common gene mutations in non‐small cell lung carcinoma (NSCLC) in Macao, and explore the relationship between each gene mutation and clinicopathologic features and survival. Methods EGFR, KRAS and BRAF mutations were detected by PCR in 122 cases of NSCLC. ALK translocation and MET amplification were detected by fluorescence in situ hybridization (FISH). MET and thyroid transcription factor (TTF‐1) were investigated by immunohistochemistry. Clinical data were collected for analyzing their correlation with the gene mutations. Results The mutation of EGFR, KRAS and BRAF was detected in 48 (39.3%), 13 (10.7%) and 3 (2.5%) of 122 cases of NSCLC, respectively. ALK translocation and MET amplification were detected in 7 (5.7%) and 3 cases (2.5%). The rate of EGFR mutation was significantly higher in female and non‐smoker patients. In TTF‐1 positive cases EGFR mutation was more frequent. Age of the patients over 62‐year old was correlated with KRAS mutations. The concordance between ALK IHC and FISH was 58.3%. The MET protein in the cases with MET amplification was 100% positive. The survival was lower in the patients with positive MET protein than those with negative. MET protein was an independent prognostic factor for NSCLC. Conclusions EGFR mutation occurred frequently in the female never smoke patients with NSCLC. KRAS mutation was more common in old patients. Negative MET protein expression could be used as a negative predictive marker of MET amplification. MET protein expression was an independent prognostic factor for NSCLC.